Virtus Fund Advisers’s BioMarin Pharmaceuticals BMRN Stock Holding History

Virtus Fund Advisers’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	$960K	Buy	+10,766	New	+$936K	0.01%	297

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Virtus Fund Advisers's BMRN Position: Q4 2017 in Review

Virtus Fund Advisers opened a new position in BioMarin Pharmaceuticals (BMRN) in Q4 2017: 10,766 shares worth $960K. The stake represents 0.01% of the portfolio and ranks #297 among its holdings.

438 funds tracked by Wall St. Rank hold BMRN as of Q4 2017.

Virtus Fund Advisers held 10,766 shares of BioMarin Pharmaceuticals worth $960K as of Q4 2017.
BioMarin Pharmaceuticals was a new Virtus Fund Advisers position in Q4 2017.
BioMarin Pharmaceuticals made up 0.01% of Virtus Fund Advisers's portfolio in Q4 2017, its #297 holding.
438 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2017.

Based on Virtus Fund Advisers's 13F filing for Q4 2017, filed 9 Feb 2018.